Welcome to our dedicated page for MYRIAD GENETICS SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
MYRIAD GENETICS INC (MYGN) reported that its Chief Financial Officer, Benjamin Richard Wheeler, had 2,555 shares of common stock withheld on September 21, 2026 to satisfy tax withholding obligations linked to vesting restricted stock units. The shares were valued at $4.01 per share for this purpose. After this withholding, Wheeler directly holds 287,193 shares of MYGN common stock. No Rule 10b5-1 trading plan is reported for this transaction.
MYRIAD GENETICS INC (MYGN) disclosed an "Exit" Form 4 for Brian J. Donnelly, who, effective September 16, 2026, no longer serves as Chief Commercial Officer and is therefore no longer subject to Section 16 reporting. The filing reports Donnelly’s continuing direct holdings of common stock and performance-based restricted stock units, but no new transactions or trades. No Rule 10b5-1 plan is reported.
MYRIAD GENETICS INC (symbol: MYGN) is the issuer of record for a Form 4 filing submitted to the SEC. Sikri Vishal reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC (MYGN) reported that EVP, Commercial Vishal Sikri received a grant of 257,731 time-based restricted stock units of common stock on September 16, 2026. The award was made under the company’s 2026 Equity Incentive Plan and vests in three equal annual installments.
Each restricted stock unit represents a contingent right to receive one share of common stock. Following this grant, Sikri holds 351,224 shares of MYGN common stock directly. No Rule 10b5-1 trading plan is reported for this award.
MYRIAD GENETICS INC (MYGN) reported an initial statement of beneficial ownership for Vishal Sikri, who serves as EVP, Commercial. The filing lists 93,493 shares of Common Stock held with direct ownership after the reported event, and does not report any concurrent purchases, sales, or derivative positions.
Myriad Genetics, Inc. (MYGN) reported leadership changes in its commercial organization and reaffirmed its previously announced 2026 financial guidance. Effective September 16, 2026, Brian Donnelly ceased serving as Chief Commercial Officer and is expected to remain as a non-executive employee through September 21, 2026 to help transition his responsibilities.
The board appointed Vishal Sikri, formerly Senior Vice President, Product, as Executive Vice President, Commercial, effective September 16, 2026. Myriad highlighted Sikri’s molecular diagnostics and oncology experience and stated that it is reaffirming its full-year 2026 financial guidance announced on July 30, 2026.
MYRIAD GENETICS INC (MYGN) reported a Form 4 for Chief Legal Officer Jennifer Lynne Fox showing that on September 3, 2026, 4,398 shares of Common Stock were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. These withheld shares were treated as a disposition for reporting purposes at $3.23 per share, based on the closing price on that date, and were not an open-market sale. After this tax-withholding event, Fox directly held 305,964 shares of MYGN Common Stock. No Rule 10b5-1 trading plan is reported for this transaction.
MYRIAD GENETICS INC (MYGN) is reported to have 9,900,937 shares of its common stock beneficially owned by BlackRock Portfolio Management LLC and certain related business units of BlackRock, Inc., representing 10.4% of the class as of the filing.
BlackRock Portfolio Management LLC reports sole power to vote 8,751,792 shares and sole power to dispose of 9,900,937 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Myriad Genetics’ outstanding common shares.
MYRIAD GENETICS INC executive Benjamin Richard Wheeler, Chief Financial Officer, reported a Form 4 transaction involving company common stock. On August 16, 2026, 8,761 shares were withheld by the issuer to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. After this tax-withholding disposition, Wheeler’s directly held common stock position is 289,748 shares.
Myriad Genetics, Inc. received an updated ownership report from Glenview Capital Management, LLC and Larry Robbins. As of June 30, 2026, the reporting persons state they may be deemed the beneficial owners of 0 shares of Myriad Genetics common stock, representing 0% of the outstanding shares. The filing confirms they hold no sole or shared voting or dispositive power over any Myriad Genetics shares, indicating they no longer report a significant ownership position in the company.
Myriad Genetics, Inc. has a new large shareholder disclosure from Vestal Point Capital, LP and its Chief Investment Officer, Ryan Wilder. The reporting group states beneficial ownership of 5,735,000 shares of Myriad Genetics common stock, representing 6.1% of the outstanding shares.
The stake is held through a Vestal Point fund and a managed account, for which Vestal Point Capital, LP acts as investment adviser. The reporting persons report shared voting and dispositive power over all 5,735,000 shares and no sole voting or dispositive power. The ownership percentage is based on 94,448,210 shares of common stock outstanding as of May 1, 2026.